Author: chris

09.05.2024

Visgenx Announces Presentation of Data Supporting Potential of its Synthetic AAV DNA...

»

09.05.2024

ASGCT 2024 Poster Abstract

»

07.05.2024

ELOVL2 Enzyme Product Improves Retinal Function and Rejuvenates Retina Architecture in an...

»

04.05.2024

Visgenx to Present at the Second Annual 2024 Cell & Gene Therapy...

»

07.12.2023

Visgenx and Charles River Announce Expansion of Gene Therapy Manufacturing Alliance

»

15.11.2023

Visgenx to Present at the 4th Annual Dry AMD Therapeutic Development Summit

»

25.10.2023

Visgenx Announces Issuance of a U.S. Patent Claiming Compositions of Candidate ELOVL2...

»

11.09.2023

Visgenx Poster: Advancing Next Generation Therapies, West Coast Symposium

»

11.09.2023

Visgenx Presents Poster at the Cell and Gene Therapy: Advancing Next Generation...

»

29.06.2023

Visgenx Announces Positive Results from a Key Translational Study for its Gene...

»

05.06.2023

Visgenx Appoints William Pedranti as Chief Executive Officer

»

24.05.2023

Attending BIO 2023? Click below to send Visgenx a meeting request in the...

»

15.05.2023

Visgenx to present at the American Society of Gene and Cell Therapy...

»